LITMUS Molecular Design
(“LMD” or “the Company”)
Spectral ModelingTM technology substantiated through creation of antipsychotic bank of drug candidates
LITMUS Molecular Design is pleased to announce that it has successfully created two antipsychotic drug candidates with third party confirmation of predicted biological activities via in vitro testing. The two drug candidates are the first to have been designed, synthesized and → Continue reading »
Subscribe
What is this?